Skip to content
HowShorted

Clovis Oncology, Inc. short interest in 2018

In 2018, Clovis Oncology, Inc.'s disclosed short interest ran from 14.79% of shares outstanding on 12 Jan 2018 to 21.05% on 31 Dec 2018, a change of +6.26 percentage points. The year's high was 25.03% on 14 Dec 2018 and its low 14.50% on 31 May 2018, averaging 16.81% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.04 days on 31 Jul 2018. Full history: Clovis Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Clovis Oncology, Inc. in 2018

2018 in figures

Start of year
14.79% (12 Jan 2018)
End of year
21.05% (31 Dec 2018)
Change
+6.26 pp
High
25.03% (14 Dec 2018)
Low
14.50% (31 May 2018)
Average
16.81%
Highest days to cover
15.04 (31 Jul 2018)
SEC filings marked
8

Every report in 2018

Clovis Oncology, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201814.79%6.33
31 Jan 201815.18%4.71
15 Feb 201816.00%6.53
28 Feb 201816.24%4.25results (8-K), 10-K filed
15 Mar 201815.21%8.70
29 Mar 201815.37%8.62
13 Apr 201816.20%5.17
30 Apr 201816.08%3.98
15 May 201815.05%5.52results (8-K), 10-Q filed
31 May 201814.50%8.44
15 Jun 201814.84%7.46
29 Jun 201816.54%8.26
13 Jul 201816.33%10.34
31 Jul 201817.81%15.04
15 Aug 201816.29%5.02results (8-K), 10-Q filed
31 Aug 201815.73%12.88
14 Sep 201816.66%12.68
28 Sep 201817.45%7.31
15 Oct 201816.71%4.58
31 Oct 201816.33%1.81results (8-K)
15 Nov 201818.19%3.5110-Q filed
30 Nov 201819.82%5.74
14 Dec 201825.03%2.43
31 Dec 201821.05%4.93

See also: Clovis Oncology, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.